Grants and Contributions:
Title:
SARS-CoV-2 Point of Care Test Development
Agreement Number:
-
Agreement Value:
$1,000,000.00
Agreement Date:
Jun 18, 2020 - Sep 30, 2021
Description:
Develop and qualify a rapid Point-of-Care diagnostic test for the SARS-CoV-2 virus that causes Covid-19. The test will be run on a portable reader that will be capable of operating in a clinic or in the field using a battery power source.
Organization:
National Defence
Expected Results:
This project will result in the development of a Canadian rapid diagnostic test for SARS-COV-2 infection in patients. This will be the first rapid test based on a saliva sample from the patient. This new technology will allow mass testing of Canadians on military bases, in airports, clinics, First Nations Reserves, doctors’ offices and retirement homes, and other POC locations.
Location:
Toronto, Ontario, CA M9W 4Z4
Reference Number:
032-2020-2021-Q1-00022
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
687782351RT0001
Recipient Type:
For-profit organization
Recipient's Operating Name:
Customs Biologics
Recipient's Legal Name:
MJMG Holdings Inc. operating as Customs Biologics
Program:
Innovation for Defence Excellence and and Security
Program Purpose:
To encourage the creation of new ideas and formulate solutions to Canada’s current and future defence and security requirements
Coverage:
Canada